Gkana Androniki, Papadopoulou Androniki, Mermiri Maria, Beltsios Eleftherios, Chatzis Dimitrios, Malli Foteini, Adamou Antonis, Gourgoulianis Konstantinos, Mavrovounis Georgios, Pantazopoulos Ioannis
Department of Emergency Medicine, Faculty of Medicine, University of Thessaly, Biopolis, 41110 Larissa, Greece.
Department of Anaesthesiology, Faculty of Medicine, University of Thessaly, Biopolis, 41110 Larissa, Greece.
J Pers Med. 2022 Sep 29;12(10):1604. doi: 10.3390/jpm12101604.
Pulmonary embolism (PE) is a rather common cardiovascular disorder constituting one of the major manifestations of venous thromboembolism (VTE). It is associated with high mortality and substantial recurrence rates, and its diagnosis may be challenging, especially in patients with respiratory comorbidities. Therefore, providing a prompt and accurate diagnosis for PE through developing highly sensitive and specific diagnostic algorithms would be of paramount importance. There is sound evidence supporting the use of biomarkers to enhance the diagnosis and predict the recurrence risk in patients with PE. Therefore, several novel biomarkers, such as factor VIII, Ischemia Modified Albumin, and fibrinogen, as well as several MicroRNAs and microparticles, have been investigated for the diagnosis of this clinical entity. The present review targets to comprehensively present the literature regarding the novel diagnostic biomarkers for PE, as well as to discuss the evidence for their use in daily routine.
肺栓塞（PE）是一种相当常见的心血管疾病，是静脉血栓栓塞症（VTE）的主要表现之一。它与高死亡率和较高的复发率相关，其诊断可能具有挑战性，尤其是在患有呼吸系统合并症的患者中。因此，通过开发高度敏感和特异的诊断算法来对PE进行快速准确的诊断至关重要。有充分的证据支持使用生物标志物来加强PE患者的诊断并预测复发风险。因此，已经对几种新型生物标志物进行了研究，如因子VIII、缺血修饰白蛋白和纤维蛋白原，以及几种微小RNA和微粒，用于诊断这一临床病症。本综述旨在全面介绍关于PE新型诊断生物标志物的文献，并讨论其在日常临床中的应用证据。
